Daneng Li
@DanengLi
Followers
1K
Following
1K
Media
1
Statuses
175
GI Medical Oncologist @CityofHope. Hepatobiliary & NET Cancers. Tweets are my own opinions. RTs are not endorsements.
Los Angeles, CA
Joined May 2020
Honored to moderate this amazing session with wonderful colleagues @lisayentwin @drjasonstarr @AGangiMD and Sandy B from Penn. @NANETS1 @LACNETS #NANETS24.
Thanks @NANETS1 for the invitation to engage in a unique & insightful panel discussion on common challenges in patient-provider and provider-provider communication. #NANETS24
1
1
24
Thanks @PoHienEar. It has been amazing Co-chairing this years symposium with you. Honored to moderate this great session @cityofhope @COHMedOnc #NANETS24.
Addressing an important topic for our patients! @DanengLi @lisayentwin @AGangiMD @drjasonstarr Amy Allen thank you!!!🙏 .#NANETS2024
0
4
15
RT @CancerNetwrk: The November issue of ONCOLOGY features a wide range of articles from those focused on survivorship, multiple myeloma and….
0
3
0
Looks like an amazing presentation @lisayentwin @LACNETS Congrats. Honored to be part of the journey with you and your team.
LACNETS Director of Programs & Outreach, Lisa Yen, is at the 2024 INCA Global NET Summit in Segovia where she presented NET VITALS as an example of best practices & challenges in working with the medical community. Check out NET VITALS here: @netcancerday
0
0
9
Out now, the Methods Full article: IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma 1st global study with Atezo/bev as comparator. Hopeful for #HCC pts. @cityofhope @COHMedOnc.
tandfonline.com
Atezolizumab plus bevacizumab is a standard of care, first-line therapy for advanced hepatocellular carcinoma (HCC). Myeloid and T regulatory cells are key immunosuppressive cell types within the h...
4
6
21
RT @JournalCancer: Patient preferences should be considered when making shared decisions about cancer therapy. In this analysis, @cityofhop….
0
6
0
Happy to have this study published with @EnriqueSoto8. Patient preferences matter among older adults with cancer receiving treatment. Hope we are continuing to make Arti proud. @JournalCancer @cityofhope @COHMedOnc @WilliamDale_MD @vani_katheria @SunCanlan @minasedrakmd #gerionc.
Our manuscript on the priorities of older patients regarding outcomes in cancer care is out in @JournalCancer. Here , we studied which outcomes were more important for older adults starting chemo. #gerionc @cityofhope @ConquerCancerFd .FREE here ⬇️.
0
3
13
Happy to share ongoing phase I dose escalation data for CF33-hNIS @AACR #AACR24. Excellent safety and encouraging early efficacy even seen at low dose levels in refractory tumor types such as #cholangiocarcinoma #bileductcancer @cityofhope @TeamImugene @COHMedOnc @CityofHopeSurg.
American Association for #Cancer Research (@AACR) Poster Presentation: "#Oncolytic virus CF33-hNIS for the treatment of advanced cancer". Presented by Dr. Daneng Li from the @cityofhope National Comprehensive Cancer Centre. Abstract Presentation Number: CT182.Session Date and
1
4
29
Ipi/Nivo meets OS endpoint for 1st line #HCC. Will be interesting to see the data given mix of Len or Sor comparator arm. Good news for pts that prior AA in the second line setting will likely be kept.
news.bms.com
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb...
0
4
25
RT @CancerNetwrk: Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwor….
cancernetwork.com
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
0
7
0
RT @CancerTherAdvsr: Written by @vickyyyf. Featuring research by Drs Riccardo Lencioni from @Unipisa, Kuang Ming from Sun Yat-sen Universit….
0
1
0
RT @CancerNetwrk: Happening tonight, @jgong15 and @DanengLi with co-host a Twitter Spaces focused on the most important data from #GI24, do….
0
4
0
RT @CancerNetwrk: As #GI24 kicks off this weekend, mark your calendars for an exciting recap of the conference with hosts @jgong15 @DanengL….
0
4
0
Tune in to our exciting Spaces after #GI24 with @jgong15 and @DanengLi to discuss the most pertinent presentations from the conference. @ASCO @cityofhope @CSCancerCenter.
0
3
11
Honored to lead the GI cohorts from COSMIC-021. Lack of activity in gastric/GE junction tumor. Signal in #HCC that led to COSMIC312. More work needed @montypal @COHMedOnc @cityofhope Cabozantinib plus atezolizumab in previously untreated advanced hepato.
0
2
13
Look forward to this upcoming exciting #SITC program to discuss the next generation of immunotherapy in GI cancers. Come join us. @cityofhope @COHMedOnc @jgong15 @MarkYarchoan @DrArsenOsipov.
Looking forward to an exciting #SITC program Advances in Cancer Immunotherapy: A Focus on Gastrointestinal Cancers co-chaired by our very own @DrArsenOsipov Suwicha Limvorasak @CSCancerCenter December 4 register at @MarkYarchoan @DanengLi @MikeFooteMD
0
5
15
Amazing work lead by @mgfakih and team. Great for CRC patients moving forward. @cityofhope @COHMedOnc.
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM Presidential ESMO session today by Dr. Pietrantonio! CodeBreaK 300 Phase 3 trial provides Level One Evidence for Soto + Pmab in KRAS G12C in refractory MCRC.
1
2
11
Join us for this important discussion on decision making and how to best make treatment decisions with our patients with #HCC.
🗓️ Mark Your Calendar! Join us on Oct 14th a Free Live Workshop. 👨‍⚕️ Expert advice on:.Shared Decision Making 👥.Palliative Care 🌼.End-of-Life Talks 🕊️. ⏰ 12 pm EST. 👉 Register now: #HealthcareWorkshop #SharedDecisionMaking
0
2
5
RT @CityofHopeCME: Early Bird Registration Now Available! Join us in October 27- 29, 2023 in La Quinta, CA!.https:/….
0
1
0